arrow
K

Konrad Aden

christian-albrechts-university and university hospital schleswig-holstein
H指数:32
被引数:3,708

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systematic Screening of Tryptophan Metabolism Identifies Site- and Microbiota-Dependent Signatures of Tryptophan Utilization in Experimental Colitis

系统筛选色氨酸代谢识别实验性结肠炎中色氨酸利用的位点依赖性和微生物群依赖性特征

2026-08-110
PRE
Tracing NAD+ metabolism uncovers adaptive coordination between host and microbiome during colitis

追踪NAD+代谢揭示结肠炎期间宿主与微生物群的适应性协调

2026-07-250
OAAI
Single-cell longitudinal profiling of peripheral blood identifies shared and therapy-specific immune signatures of early remission in ulcerative colitis

单细胞纵向分析外周血可识别溃疡性结肠炎早期缓解期共有的和疗法特异性的免疫特征

2026-01-010
PRE
Systematic screening of tryptophan metabolism identifies site- and microbial-specific signatures of tryptophan utilization in experimental colitis

系统性筛选色氨酸代谢,鉴定实验性结肠炎中色氨酸利用的位点特异性和微生物特异性特征

2026-01-010
PRE
Biomarker-informed therapy guidance improved clinical outcomes of anti-tumour necrosis factor treatment in patients with inflammatory bowel disease in a multi-centre, randomized, controlled, open-label, prospective clinical trial (GUIDE-IBD)

生物标志物指导的疗法改善了炎症性肠病患者抗肿瘤坏死因子治疗的临床结局:一项多中心、随机、对照、开放标签、前瞻性临床试验(GUIDE-IBD)

2026-01-010
PRE
Type I and II interferon blood signatures correlate with ultrasound markers of intestinal fibrostenosis and predict surgical outcomes in Crohn's disease

I型和II型干扰素血液特征与克罗恩病肠道纤维狭窄的超声标志物相关,并能预测手术结局

2026-01-010
PRE
Cross-species engraftment biases and metabolic divergence in gnotobiotic mice humanized with ulcerative colitis microbiota

跨物种移植偏倚及在接种溃疡性结肠炎微生物群的悉生小鼠中的代谢差异

2025-11-240
OAAI
Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4+ T cells to confer protection against intestinal inflammation

微生物代谢产物吲哚-3-丙酸驱动CD4+ T细胞线粒体呼吸,以对抗肠道炎症提供保护。

2025-10-210
OA
Atg16l1 and Xbp1 cooperatively protect from transcription-associated mutagenesis and small intestinal carcinogenesis

Atg16l1和Xbp1协同保护免受转录相关突变和小肠致癌作用

2025-10-070
OA
987e: BIOMARKER-INFORMED THERAPY GUIDANCE IMPROVED CLINICAL OUTCOMES OF ANTI-TNF TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE CLINICAL TRIAL (GUIDE-IBD)

987e: 生物标志物指导的疗法改善了炎症性肠病患者抗-TNF治疗的临床结局,该研究在一项多中心、随机、开放标签、前瞻性临床试验(GUIDE-IBD)中进行。

2025-07-030
PRE
Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease

粪便元蛋白质组学能够实现炎症性肠病患者缓解期的功能表征

2025-06-010
OA